everolimus
10 mg/1 · Tablet
By Novugen Pharma (USA) LLC.
- NDC
- 82293-033
- Route
- Oral
- Therapeutic class
- Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Decreased Immunologic Activity [PE], Kinase Inhibitor , Protein Kinase Inhibitors [MoA], mTOR Inhibitor Immunosuppressant , mTOR Inhibitors [MoA]
- Marketing category
- ANDA
Package sizes
- 1 POUCH in 1 CARTON (82293-033-31) / 3 BLISTER PACK in 1 POUCH / 10 TABLET in 1 BLISTER PACK (82293-033-30)NDC 82293-033-31Available to order
- 4 BLISTER PACK in 1 CARTON (82293-033-21) / 7 TABLET in 1 BLISTER PACK (82293-033-20)NDC 82293-033-21Available to order
- 28 TABLET in 1 BOTTLE (82293-033-10)NDC 82293-033-10Available to order
Additional information
Full prescribing information for this product is available on request. Submit a sourcing request and our team will share lot details, dating, and current pricing.
Request this medication
Send a request and we'll respond with availability, lot details, and pricing within 2 business hours.
Related in Oncology & Specialty
See all →Verzenio (abemaciclib)
50 mg/1 · Tablet
Eli Lilly and Company
Available to source
Verzenio (abemaciclib)
200 mg/1 · Tablet
Eli Lilly and Company
Available to source
Verzenio (abemaciclib)
100 mg/1 · Tablet
Eli Lilly and Company
Available to source
Verzenio (abemaciclib)
150 mg/1 · Tablet
Eli Lilly and Company
Available to source
